Dengue fever

From Wikipedia, the free encyclopedia

Jump to: navigation, search
"Dengue Fever" redirects here. For the band of the same name, see Dengue Fever (band).
Dengue fever
Classification and external resources
ICD-10 A90.
ICD-9 061
DiseasesDB 3564
MedlinePlus 001374
eMedicine med/528
MeSH C02.782.417.214
Dengue virus

A TEM micrograph showing Dengue

virus virions (the cluster of dark dots
near the center).
Virus classification
Group: Group IV ((+)ssRNA)
Family: Flaviviridae
Genus: Flavivirus
Species: Dengue virus

Dengue fever (pronounced UK: /ˈdɛŋɡeɪ/, US: /ˈdɛŋɡiː/) and dengue hemorrhagic fever
(DHF) are acute febrile diseases which occur in the tropics, can be life-threatening, and
are caused by four closely related virus serotypes of the genus Flavivirus, family
Flaviviridae.[1] It is also known as breakbone fever, since it can be extremely painful. It
occurs widely in the tropics, including northern Argentina, northern Australia,
Bangladesh, Barbados, Bolivia[2], Belize, Brazil, Cambodia, Colombia, Costa Rica, Cuba,
Dominican Republic, French Polynesia, Guadeloupe, El Salvador, Guatemala, Guyana,
Haiti, Honduras, India, Indonesia, Jamaica, Laos, Malaysia, Melanesia, Mexico,
Micronesia, Nicaragua, Pakistan, Panama, Paraguay[3], Philippines, Puerto Rico, Samoa[4],
Western Saudi Arabia, Singapore, Sri Lanka, Suriname, Taiwan, Thailand, Trinidad,
Venezuela and Vietnam, and increasingly in southern China[5]. Unlike malaria, dengue is
just as prevalent in the urban districts of its range as in rural areas. Each serotype is
sufficiently different that there is no cross-protection and epidemics caused by multiple
serotypes (hyperendemicity) can occur. Dengue is transmitted to humans by the Aedes
(Stegomyia) aegypti or more rarely the Aedes albopictus mosquito, both of which feed
exclusively during daylight hours. [6]

The WHO says some 2.5 billion people, two fifths of the world's population, are now at
risk from dengue and estimates that there may be 50 million cases of dengue infection
worldwide every year. The disease is now endemic in more than 100 countries.[7]

Contents
[hide]

• 1 Signs and symptoms

• 2 Cause
o 2.1 DENV
o 2.2 DENV E and M Proteins and the Assembly and Maturation of the Viral
Glycoprotein Shell
 2.2.1 E protein
 2.2.2 prM/M protein
o 2.3 Non-Structural proteins
 2.3.1 NS3 protein
 2.3.2 NS5 protein
• 3 Diagnosis
• 4 Prevention
o 4.1 Vaccine development
• 5 Treatment
• 6 Epidemiology
o 6.1 Recent outbreaks
o 6.2 Blood transfusion
• 7 History
o 7.1 Etymology
o 7.2 History of the literature
• 8 Society and culture
o 8.1 Use as a biological weapon
• 9 Research
o 9.1 Wolbachia
 o 9.2 Antiviral approaches
o 9.3 Sterile insect technique
• 10 See also
• 11 References

• 12 External links

[edit] Signs and symptoms

The disease manifests as fever of sudden onset associated with headache, muscle and
joint pains (myalgias and arthralgias—severe pain that gives it the nickname break-bone
fever or bonecrusher disease), distinctive retro-orbital pain, and rash.[8] The classic
dengue rash is a generalised maculopapular rash with islands of sparing. A hemorrhagic
rash of characteristically bright red pinpoint spots, known as petechiae can occur later
during the illness and is associated with thrombocytopenia. It usually appears first on the
lower limbs and the chest; in some patients, it spreads to cover most of the body. There
may also be severe retro-orbital pain, (a pain from behind the eyes that is distinctive to
Dengue infections), and gastritis with some combination of associated abdominal pain,
nausea, vomiting coffee-grounds-like congealed blood, or diarrhea. Some cases develop
much milder symptoms which can be misdiagnosed as influenza or other viral infection
when no rash or retro-orbital pain is present. Febrile travelers from tropical areas may
transmit dengue inadvertently to previously Dengue free populations of Aedes
(Stegomyia) Aegypti mosquitoes, having not been properly diagnosed for Dengue.
Patients only transmit Dengue when they are febrile and bitten by Aedes (Stegomyia)
Aegypti mosquitoes, or (much more unusually) via blood products. The classic dengue
fever lasts about two to seven days, with a smaller peak of fever at the trailing end of the
disease (the so-called "biphasic pattern"). Clinically, the platelet count will drop until
after the patient's temperature is normal. Cases of DHF also show higher fever, variable
hemorrhagic phenomena including bleeding from the eyes,nose,mouth and ear into the
gut, and oozing blood from skin pores, thrombocytopenia, and hemoconcentration. When
Dengue infections proceed to DHF symptoms, DHF causes vascular leak syndrome
which includes fluid in the blood vessels leaking through the skin and into spaces around
the lungs and belly. This fluid loss and severe bleeding can cause blood pressure to fall,
then Dengue Shock Syndrome (DSS) sets in, which has a high mortality rate.

[edit] Cause
[edit] DENV

Dengue fever is caused by Dengue virus (DENV), a mosquito-borne flavivirus. DENV is

an ssRNA positive-strand virus of the family Flaviviridae; genus Flavivirus. There are
four serotypes of DENV. The virus has a genome of about 11000 bases that codes for
three structural proteins, C, prM, E; seven nonstructural proteins, NS1, NS2a, NS2b,
NS3, NS4a, NS4b, NS5; and short non-coding regions on both the 5' and 3' ends.[9]
[edit] DENV E and M Proteins and the Assembly and Maturation of the
Viral Glycoprotein Shell

[edit] E protein

The DENV E (envelope) protein, found on the viral surface, is important in the initial
attachment of the viral particle to the host cell. Several molecules which interact with the
viral E protein (ICAM3-grabbing non-integrin.[10] ,CD209 [11], Rab 5 [12], GRP 78 [13], and
The Mannose Receptor [14])have been shown to be important factors mediating attachment
and viral entry.[15]

[edit] prM/M protein

The DENV prM (membrane) protein, which is important in the formation and maturation
of the viral particle, consists of seven antiparallel β-strands stabilized by three disulphide
bonds.[15]

The glycoprotein shell of the mature DENV virion consists of 180 copies each of the E
protein and M protein. The immature virion starts out with the E and prM proteins
forming 90 heretodimers that give a spiky exterior to the viral particle. This immature
viral particle buds into the endoplasmic reticulum and eventually travels via the secretory
pathway to the golgi apparatus. As the virion passes through the TGN it is exposed to low
pH. This acidic environment causes a conformational change in the E protein which
disassociates it from the prM protein and causes it to form E homodimers. These
homodimers lay flat against the viral surface giving the maturing virion a smooth
appearance. During this maturation pr peptide is cleaved from the M peptide by the host
protease, furin. The M protein then acts as a transmembrane protein under the E-protein
shell of the mature virion. The pr peptide stays associated with the E protein until the
viral particle is released into the extracellular environment. This pr peptide acts like a
cap, covering the hydrophobic fusion loop of the E protein until the viral particle has
exited the cell.[15]

[edit] Non-Structural proteins

[edit] NS3 protein

The DENV NS3 is a serine protease, as well as an RNA helicase and RTPase/NTPase.
The protease domain consists of six β-strands arranged into two β-barrels formed by
residues 1-180 of the protein. The catalytic triad (His-51, Asp-75 and Ser-135), is found
between these two β-barrels, and its activity is dependant on the presence of the NS2B
cofactor. This cofactor wraps around the NS3 protease domain and becomes part of the
active site. The remaining NS3 residues (180-618), form the three subdomains of the
DENV helicase. A six-stranded parallel β-sheet surrounded by four α-helices make up
subdomains I and II, and subdomain III is composed of 4 α-helices surrounded by three
shorter α-helices and two antiparallel β-strands.[15]
[edit] NS5 protein

The DENV NS5 protein is a 900 residue peptide with a methyltransferase domain at its
N-terminal end (residues 1-296) and a RNA-dependent RNA polymerase at its C-
terminal end (residues 320–900). The methyltransferase domain is comprised of an α/β/β
sandwich flanked by N-and C-terminal subdomains. The DENV RNA-dependent RNA
polymerase is similar to other to other RdRps containing palm, finger, and thumb
subdomains and a GDD motif for incorporating nucleotides.[15]

The potential factors causing hemorrhagic fever are varied. The most suspected factors
are human's cross-serotypic immune response and membrane fusion process.

Human antibodies produced in response to the virus actually increase the infection.[16]

[edit] Diagnosis
The diagnosis of dengue is usually made clinically. The classic picture is high fever with
no localising source of infection, a rash with thrombocytopenia and relative leukopenia -
low platelet and white blood cell count. Dengue infection can affect many organs and
thus may present unusually as liver dysfunction, renal impairment, meningo-encephalitis
or gastroenteritis.

1. Fever, headaches, eye pain, severe dizziness and loss of appetite.

2. Hemorrhagic tendency (positive tourniquet test, spontaneous bruising, bleeding
from mucosa, gingiva, injection sites, etc.; vomiting blood, or bloody diarrhea)
3. Thrombocytopenia (<100,000 platelets per mm³ or estimated as less than 3
platelets per high power field)
4. Evidence of plasma leakage (hematocrit more than 20% higher than expected, or
drop in hematocrit of 20% or more from baseline following IV fluid, pleural
effusion, ascites, hypoproteinemia)
5. Encephalitic occurrences.

Dengue shock syndrome is defined as dengue hemorrhagic fever plus:

• Weak rapid pulse,

• Narrow pulse pressure (less than 20 mm Hg)
• Cold, clammy skin and restlessness.

Dependable, immediate diagnosis of dengue can be performed in rural areas by the use of
Rapid Diagnostic Test kits, which also differentiate between primary and secondary
dengue infections.[17] Serology and polymerase chain reaction (PCR) studies are available
to confirm the diagnosis of dengue if clinically indicated. Dengue can be a life
threatening fever.

[edit] Prevention
[edit] Vaccine development

There is no tested and approved vaccine for the dengue flavivirus. There are many
ongoing vaccine development programs. Among them is the Pediatric Dengue Vaccine
Initiative set up in 2003 with the aim of accelerating the development and introduction of
dengue vaccine(s) that are affordable and accessible to poor children in endemic
countries.[18] Thai researchers are testing a dengue fever vaccine on 3,000–5,000 human
volunteers after having successfully conducted tests on animals and a small group of
human volunteers.[19] A number of other vaccine candidates are entering phase I or II
testing.[20] As of July 2010, the National Institutes of Health reported on their
ClinicalTrials.Gov Web site that there were 19 vaccines undergoing testing or recruiting
for participants. [21] Because exposure to one of dengue's 4 serotypes provides no
immunity against infection by the other types, and may make the patient susceptible to
more severe disease symptoms, testing vaccines must be performed carefully, and usually
not in areas where the disease is endemic for fear that even attenuated virus vaccines may
cause severe reactions.[22]

In 1998, scientists from the Queensland Institute of Medical Research (QIMR) in

Australia and Vietnam's Ministry of Health introduced a scheme that encouraged children
to place a water bug, the crustacean Mesocyclops, in water tanks and discarded containers
where the Aedes aegypti mosquito was known to thrive.[23] This method is viewed as
being more cost-effective and more environmentally friendly than pesticides, though not
as effective, and requires the continuing participation of the community.[24]

Even though this method of mosquito control was successful in rural provinces, not much
is known about how effective it could be if applied to cities and urban areas. The
Mesocyclops can survive and breed in large water containers but would not be able to do
so in small containers that most urban dwellers have in their homes. Also, Mesocyclops
are hosts for the guinea worm, a pathogen that causes a parasite infection, and so this
method of mosquito control cannot be used in countries that are still susceptible to the
guinea worm. The biggest dilemma with Mesocyclops is that its success depends on the
participation of the community. This idea of a possible parasite-bearing creature in
household water containers dissuades people from continuing the process of inoculation
and, without the support and work of everyone living in the city, this method will not be
successful.[25]

[edit] Treatment
The mainstay of treatment is timely supportive therapy to tackle circulatory shock due to
hemoconcentration and bleeding. Close monitoring of vital signs in the critical period (up
to 2 days after defervescence - the departure or subsiding of a fever) is critical. Increased
oral fluid intake is recommended to prevent dehydration. Supplementation with
intravenous fluids may be necessary to prevent dehydration and significant concentration
of the blood if the patient is unable to maintain oral intake. A platelet transfusion may be
indicated if the platelet level drops significantly (below 20,000) or if there is significant
bleeding. The presence of melena may indicate internal gastrointestinal bleeding
requiring platelet and/or red blood cell transfusion.

Aspirin and non-steroidal anti-inflammatory drugs should be avoided as these drugs may
worsen the bleeding tendency associated with some of these infections. Patients may
receive paracetamol, acetaminophen, preparations to deal with these symptoms if dengue
is suspected.[26]

[edit] Epidemiology

Disability-adjusted life year for dengue fever per 100,000 inhabitants in 2002.
no data < 15 15-30 30-45 45- 90-105 105-120 120-135 135-
60 60-75 75-90 150 150-250 > 250

Worldwide dengue distribution, 2006. Red: Epidemic dengue. Blue: Aedes aegypti.

Worldwide dengue distribution, 2000.

Dengue is transmitted by Aedes mosquitoes, particularly A. aegypti and A. albopictus.

The first recognized Dengue epidemics occurred almost simultaneously in Asia, Africa,
and North America in the 1780s, shortly after the identification and naming of the disease
in 1779. A pandemic began in Southeast Asia in the 1950s, and by 1975 DHF had
become a leading cause of death among children in the region. Epidemic dengue has
become more common since the 1980s. By the late 1990s, dengue was the most
important mosquito-borne disease affecting humans after malaria, with around 40 million
cases of dengue fever and several hundred thousand cases of dengue hemorrhagic fever
each year. Significant outbreaks of dengue fever tend to occur every five or six months.
The cyclical rise and fall in numbers of dengue cases is thought to be the result of
seasonal cycles interacting with a short-lived cross-immunity[clarification needed] for all four
strains in people who have had dengue. When the cross-immunity wears off the
population is more susceptible to transmission whenever the next seasonal peak occurs.
Thus over time there remain large numbers of susceptible people in affected populations
despite previous outbreaks due to the four different serotypes of dengue virus and the
presence of unexposed individuals from childbirth or immigration.

There is significant evidence, originally suggested by S.B. Halstead in the 1970s, that
dengue hemorrhagic fever is more likely to occur in patients who have secondary
infections by another one of dengue fever's four serotypes. One model to explain this
process is known as antibody-dependent enhancement (ADE), which allows for increased
uptake and virion replication during a secondary infection with a different strain.
Through an immunological phenomenon, known as original antigenic sin, the immune
system is not able to adequately respond to the stronger infection, and the secondary
infection becomes far more serious.[27]

Reported cases of dengue are an under-representation of all cases when accounting for
subclinical cases and cases where the patient did receive medical treatment.

There was a serious outbreak in Rio de Janeiro in February 2002 affecting around one
million people and killing sixteen. On March 20, 2008, the secretary of health of the state
of Rio de Janeiro, Sérgio Côrtes, announced that 23,555 cases of dengue, including 30
deaths, had been recorded in the state in less than three months. Côrtes said, "I am
treating this as an epidemic because the number of cases is extremely high." Federal
Minister of Health, José Gomes Temporão also announced that he was forming a panel to
respond to the situation. Cesar Maia, mayor of the city of Rio de Janeiro, denied that
there was serious cause for concern, saying that the incidence of cases was in fact
declining from a peak at the beginning of February.[28] By April 3, 2008, the number of
cases reported rose to 55,000 [29]

In Singapore, there are 4,000–5,000 reported cases of dengue fever or dengue

haemorrhagic fever every year. In the year 2004, there were seven deaths from dengue
shock syndrome.[30]

[edit] Recent outbreaks

Main articles: 2005 dengue outbreak in Singapore, 2006 dengue outbreak in India, 2006
dengue outbreak in Pakistan, and 2009 Bolivian dengue fever epidemic
An outbreak of dengue fever was declared in Cairns, located in the tropical north of
Queensland, Australia on 1 December 2008. As of 3 March 2009 there were 503
confirmed cases of dengue fever, in a residential population of 152,137. Outbreaks were
subsequently declared the neighbouring cities and towns of Townsville (outbreak
declared 5 January 2009), Port Douglas (6 February 2009), Yarrabah (19 February 2009),
Injinoo (24 February 2009), Innisfail (27 February 2009) and Rockhampton (10 March
2009). There have been occurrences of dengue types one, two, three, and four in the
region. On March 4, 2009, Queensland Health had confirmed an elderly woman had died
from dengue fever in Cairns, in the first fatality since the epidemic began last year. The
statement said that although the woman had other health problems, she tested positive for
dengue and the disease probably contributed to her death.

An epidemic broke out in Bolivia in early 2009, in which 18 people have died and 31,000
infected.

In 2009, in Argentina, a dengue outbreak was declared the northern provinces of Chaco,
Catamarca, Salta, Jujuy, and Corrientes, with over 9673 cases reported as of April 11,
2009 by the Health Ministry [3]. Some travelers from the affected zones have spread the
fever as far south as Buenos Aires [4]. Major efforts to control the epidemic in Argentina
are focused on preventing its vector (the Aedes mosquitoes) from reproducing. This is
addressed by asking people to dry out all possible water reservoirs from where
mosquitoes could proliferate (which is, in other countries, known as "descacharrado").
There have also been information campaigns concerning prevention of the dengue fever;
and the government is fumigating with insecticide in order to control the mosquito
population.[31]

The first cases of dengue fever have recently been reported on the island nation of
Mauritius in the Indian Ocean. One of the South Asian countries still suffering highly
from this problem is Sri Lanka.[32]

[edit] Blood transfusion

Dengue may also be transmitted via infected blood products (blood transfusions, plasma,
and platelets),[33][34] and in countries such as Singapore, where dengue is endemic, the risk
was estimated to be between 1.6 and 6 per 10,000 blood transfusions.[35]

[edit] History
[edit] Etymology

The origins of the word dengue are not clear, but one theory is that it is derived from the
Swahili phrase "Ka-dinga pepo", which describes the disease as being caused by an evil
spirit.[36] The Swahili word "dinga" may possibly have its origin in the Spanish word
"dengue" meaning fastidious or careful, which would describe the gait of a person
suffering the bone pain of dengue fever.[37] Alternatively, the use of the Spanish word
may derive from the similar-sounding Swahili.[38]
[edit] History of the literature

Slaves in the West Indies who contracted dengue were said to have the posture and gait
of a dandy, and the disease was known as "Dandy Fever".[39] The first record of a case of
probable dengue fever is in a Chinese medical encyclopedia from the Jin Dynasty (265–
420 AD) which referred to a “water poison” associated with flying insects.[38] The first
confirmed case report dates from 1789 and is by Benjamin Rush, who coined the term
"breakbone fever" because of the symptoms of myalgia and arthralgia.[40] The viral
etiology and the transmission by mosquitoes were discovered in the 20th century by Sir
John Burton Cleland.

Population movements during World War II spread the disease globally. A pandemic of
dengue began in Southeast Asia after World War II and has spread around the globe since
then.[41]

[edit] Society and culture

[edit] Use as a biological weapon

Dengue fever was one of more than a dozen agents that the United States researched as
potential biological weapons before the nation suspended its biological weapons
program.[42]

[edit] Research
Emerging evidence suggests that mycophenolic acid and ribavirin inhibit dengue
replication. Initial experiments showed a fivefold increase in defective viral RNA
production by cells treated with each drug.[43] In vivo studies, however, have not yet been
done. Unlike HIV therapy, lack of adequate global interest and funding greatly hampers
the development of a treatment regime.

[edit] Wolbachia

In 2009, scientists from the School of Integrative Biology at The University of

Queensland revealed that by infecting Aedes mosquitos with the bacterium Wolbachia,
the adult lifespan was reduced by half.[44] In the study, super-fine needles were used to
inject 10,000 mosquito embryos with the bacterium. Once an insect was infected, the
bacterium would spread via its eggs to the next generation. A pilot release of infected
mosquitoes could begin in Vietnam within three years. If no problems are discovered, a
full-scale biological attack against the insects could be launched within five years.[45]

[edit] Antiviral approaches

Dengue virus belongs to the family Flaviviridae, which includes the hepatitis C virus,
West Nile and Yellow fever viruses among others. Possible laboratory modification of
the yellow fever vaccine YF-17D to target the dengue virus via chimeric replacement has
been discussed extensively in scientific literature,[46] but as of 2009 no full scale studies
have been conducted.[47]

In 2006 a group of Argentine scientists discovered the molecular replication mechanism

of the virus, which could be specifically attacked by disrupting the viral RNA
polymerase.[48] In cell culture[49] and murine experiments[50][51] morpholino antisense
oligomers have shown specific activity against Dengue virus.

[edit] Sterile insect technique

The sterile insect technique, a form of biological control, has long proved difficult with
mosquitos because of the fragility of the males.[52] However, a transgenic strain of Aedes
aegypti was announced in 2010 which might alleviate this problem: the strain produces
females that are flightless due to a mis-development of their wings,[53] and so can neither
mate nor bite. The genetic defect only causes effects in females, so that males can act as
silent carriers.[52]

[edit] See also

• Dengue fever at the Open Directory Project
• Dengue Virus Genomes database search results from the Dengue Virus Database
at the Viral Bioinformatics Resource Center
• Discovering Dengue Drugs – Together, a distributed computing project
attempting to identify drug leads with broad spectrum activity against dengue.[54]
• Dengue Fever Alliance - Todos Frente al Dengue Alliance to strengthen the
capacity of action and management for A World Free of Dengue Fever

[edit] References
1. ^ "Chapter 4, Prevention of Specific Infectious Diseases". CDC Traveler's Health:
Yellow Book. http://www2.ncid.cdc.gov/travel/yb/utils/ybGet.asp?
section=dis&obj=dengue.htm. Retrieved 2007-05-20.
2. ^ "Dengue fever outbreak in Bolivia". BBC. 2009-02-03.
http://news.bbc.co.uk/2/hi/americas/7866908.stm. Retrieved 2009-02-26.
3. ^ Reuters, "Dengue Fever Hits Paraguay", New York Times" (March 4, 2007)
4. ^ http://www.samoalivenews.com/Health/Dengue-Fever-Outbreak-Confirmed-In-
Samoa.html
5. ^ "Zhuhai reports outbreak of dengue fever". China Daily. 200-09-06.
http://www.chinadaily.com.cn/china/2007-09/06/content_6087035.htm. Retrieved
2009-11-18.
6. ^ Dengue Fever – Information Sheet. World Health Organization, October 9,
2006. Retrieved on 2007-11-30.
7. ^ Dengue epidemic threatens India's capital
8. ^ Ryan KJ, Ray CG (editors) (2004). Sherris Medical Microbiology (4th ed.).
McGraw Hill. pp. 592. ISBN 0838585299.
9. ^ Hanley, K.A. and Weaver, S.C. (editors) (2010). Frontiers in Dengue Virus
Research. Caister Academic Press. ISBN 978-1-904455-50-9.
10. ^ ,Navarro-Sanchez E, et al. Dendritic-cell-specific ICAM3-grabbing non-
integrin is essential for the productive infection of human dendritic cells by
mosquito-cell-derived dengue viruses. EMBO Rep 2003;4:723–728.
11. ^ ,Tassaneetrithep, B et al. DC-SIGN (CD209) mediates dengue virus infection of
human dendritic cells. J Exp Med 2003;197:823–829.
12. ^ ,Krishnan, MN et al. Rab 5 is required for the cellular entry of dengue and West
Nile viruses. J Virol 2007;81:4881–4885.
13. ^ ,Jindadamrongwech, S et al. Identification of GRP 78 (BiP) as a liver cell
expressed receptor element for dengue virus serotype 2. Arch Virol
2004;149:915–927.
14. ^ , Miller, JL et al. The Mannose Receptor Mediates Dengue Virus Infection of
Macrophages. PLoS Pathog 2008;4:e17.
15. ^ a b c d e ,Perera, Rushika and Kuhn, Richard J. Structural Proteomics of Dengue
Virus. Curr Opin Microbiol. 2008 August ; 11(4): 369–377.
16. ^ Dejnirattisai, W.; Jumnainsong, A.; Onsirisakul, N.; Fitton, P.; Vasanawathana,
S.; Limpitikul, W.; Puttikhunt, C.; Edwards, C. et al. (2010). "Cross-Reacting
Antibodies Enhance Dengue Virus Infection in Humans". Science 328 (5979):
745. doi:10.1126/science.1185181. PMID 20448183. Lay summary. edit
17. ^ Such a diagnostic kit may consist of a "test cassette" or other device. One type
is described as follows: "Dengue fever rapid test devices, also known as one-step
dengue tests, are a solid phase immuno-chromatographic assay for the rapid,
qualitative and differential detection of dengue IgG and IgM antibodies to dengue
fever virus in human serum, plasma or whole blood." Atlas Link Biotech co. Ltd
(2008)Dengue Fever Rapid Test Kits. Accessed: 27/06/09. Available at:
http://www.ivdpretest.com/Dengue-Rapid-Tests.html
18. ^ "Pediatric Dengue Vaccine Initiative". 2008. http://www.pdvi.org/. Retrieved
2008-10-05.
19. ^ "Thailand to test Mahidol-developed dengue vaccine prototype". People's Daily
Online. 2005-09-05.
http://english.people.com.cn/200509/05/eng20050905_206569.html. Retrieved
2006-10-08.
20. ^ Edelman R (July 2007). "Dengue vaccines approach the finish line". Clinical
infectious diseases : an official publication of the Infectious Diseases Society of
America 45 Suppl 1: S56–60. doi:10.1086/518148. PMID 17582571.
http://www.journals.uchicago.edu/doi/abs/10.1086/518148?url_ver=Z39.88-
2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dncbi.nlm.nih.gov.
21. ^ [1]
22. ^ [2]
23. ^ Vu SN, Nguyen TY, Kay BH, Marten GG, Reid JW (1 October 1998).
"Eradication of Aedes aegypti from a village in Vietnam, using copepods and
community participation". Am J Trop Med Hyg. 59 (4): 657–60. PMID 9790448.
http://www.ajtmh.org/cgi/pmidlookup?view=long&pmid=9790448.
24. ^ "Water bug aids dengue fever fight". BBC News. 2005-02-11.
http://news.bbc.co.uk/1/hi/health/4257935.stm. Retrieved 2008-10-05.
Kay B, Vu SN (2005). "New strategy against Aedes aegypti in Vietnam". Lancet
365 (9459): 613–7. doi:10.1016/S0140-6736(05)17913-6. PMID 15708107.
25. ^ "Control of aedes vectors of dengue in three provinces of Vietnam by use of
Mesocyclops (Copepoda) and community-based methods validated by
entomologic, clinical, and serological surveillance". The American Society of
Tropical Medicine and Hygiene. 2002.
http://www.ajtmh.org/cgi/content/abstract/66/1/40. Retrieved 2009-02-18.
26. ^ "Dengue & DHF: Information for Health Care Practitioners". Dengue Fever.
CDC Division of Vector-Borne Infectious Diseases (DVBID). 2007-10-22.
http://www.cdc.gov/NCIDOD/dvbid/dengue/dengue-hcp.htm. Retrieved 2008-10-
05.
27. ^ Rothman AL (2004). "Dengue: defining protective versus pathologic
immunity". J. Clin. Invest. 113 (7): 946–51. doi:10.1172/JCI200421512.
PMID 15057297.
28. ^ Fernanda Pontes (20 March 2008). "Secretário estadual de Saúde Sérgio Côrtes
admite que estado vive epidemia de dengue" (in Portuguese). O Globo Online.
http://oglobo.globo.com/rio/mat/2008/03/20/secretario_estadual_de_saude_sergio
_cortes_admite_que_estado_vive_epidemia_de_dengue-426368388.asp..
29. ^ CNN (3 April 2008). "Thousands hit by Brazil outbreak of dengue". CNN.
http://www.cnn.com/2008/HEALTH/conditions/04/03/brazil.dengue/index.html.
30. ^ http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B7CPT-
4KKNNH5-
2&_user=130561&_rdoc=1&_fmt=&_orig=search&_sort=d&view=c&_acct=C0
00010878&_version=1&_urlVersion=0&_userid=130561&md5=4cc1b9743b4fd
df5a0567b16b99bc130
31. ^ Marcos Wozniak (12 March 2009).
32. ^ Sri Lanka
33. ^ Wilder-Smith A, Chen LH, Massad E, Wilson ME (2009). "Threat of dengue to
blood safety in dengue-endemic countries". Emerg Infect Dis 15 (1): 8–11.
doi:10.3201/eid1501.071097. PMID 19116042.
34. ^ Stramer SL, Hollinger FB, Katz LM, Kleinman S, Metzel PS, Gregory KR,
Dodd RY (2009). "Emerging infectious disease agents and their potential threat to
transfusion safety.". Transfusion 49 (Suppl 2): 1–29. doi:10.1111/j.1537-
2995.2008.02019.x. PMID 19686562.
35. ^ Teo D, Ng LC, Lam S (2009). "Is dengue a threat to the blood supply?".
Transfus Med 19 (2): 66–77. doi:10.1111/j.1365-3148.2009.00916.x.
PMID 19392949.
36. ^ "Dengue fever: essential data". 1999.
http://www.cbwinfo.com/Biological/Pathogens/DENV.html#0009. Retrieved
2008-10-05.
37. ^ Harper D (2001). "Etymology: dengue". Online Etymology Dictionary.
http://www.etymonline.com/index.php?term=dengue. Retrieved 2008-10-05.
38. ^ a b "etymologia: dengue" (PDF). Emerging Infectious Diseases 12 (6): 893.
2006. http://www.cdc.gov/ncidod/eid/vol12no06/pdfs/etymology.pdf.
39. ^ url=http://www.medterms.com/script/main/art.asp?articlekey=6620
40. ^ Gubler DJ (July 1998). "Dengue and dengue hemorrhagic fever". Clinical
microbiology reviews 11 (3): 480–96. PMID 9665979. PMC 88892.
http://cmr.asm.org/cgi/pmidlookup?view=long&pmid=9665979.
41. ^ Dengue Fever Fact Sheet. CDC.
42. ^ "Chemical and Biological Weapons: Possession and Programs Past and
Present", James Martin Center for Nonproliferation Studies, Middlebury College,
April 9, 2002, accessed November 14, 2008.
43. ^ Takhampunya R, Ubol S, Houng HS, Cameron CE, Padmanabhan R (2006).
"Inhibition of dengue virus replication by mycophenolic acid and ribavirin". J.
Gen. Virol. 87 (Pt 7): 1947–52. doi:10.1099/vir.0.81655-0. PMID 16760396.
http://vir.sgmjournals.org/cgi/content/full/87/7/1947.
44. ^ McMeniman CJ, Lane RV, Cass BN, et al. (January 2009). "Stable Introduction
of a Life-Shortening Wolbachia Infection into the Mosquito Aedes aegypti".
Science 323 (5910): 141–4. doi:10.1126/science.1165326. PMID 19119237.
http://www.sciencemag.org/cgi/content/abstract/323/5910/141.
45. ^ "Dengue fever breakthrough". Sydney Morning Herald. 2009-01-02.
http://www.smh.com.au/news/specials/science/dengue-fever-
breakthrough/2009/01/02/1230681699070.html. Retrieved 2009-01-02.
46. ^ Lai CJ, Monath TP (2003). "Chimeric flaviviruses: novel vaccines against
dengue fever, tick-borne encephalitis, and Japanese encephalitis". Advances in
virus research 61: 469–509. doi:10.1016/S0065-3527(03)61013-4.
PMID 14714441.
47. ^ Querec T, Bennouna; Bennouna, S; Alkan, S; Laouar, Y; Gorden, K; Flavell, R;
Akira, S; Ahmed, R et al. (2006). "Yellow fever vaccine YF-17D activates
multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent
immunity". J. Exp. Med. 203 (2): 413–24. doi:10.1084/jem.20051720.
PMID 16461338.
48. ^ Filomatori CV, Lodeiro MF, Alvarez DE, Samsa MM, Pietrasanta L, Gamarnik
AV (2006). "A 5' RNA element promotes dengue virus RNA synthesis on a
circular genome". Genes Dev. 20 (16): 2238–49. doi:10.1101/gad.1444206.
PMID 16882970.
49. ^ Kinney RM, Huang CY, Rose BC, et al. (April 2005). "Inhibition of dengue
virus serotypes 1 to 4 in vero cell cultures with morpholino oligomers". Journal
of virology 79 (8): 5116–28. doi:10.1128/JVI.79.8.5116-5128.2005.
PMID 15795296. PMC 1069583. http://jvi.asm.org/cgi/pmidlookup?
view=long&pmid=15795296.
50. ^ Burrer R, Neuman BW, Ting JP, et al. (June 2007). "Antiviral effects of
antisense morpholino oligomers in murine coronavirus infection models". Journal
of virology 81 (11): 5637–48. doi:10.1128/JVI.02360-06. PMID 17344287.
PMC 1900280. http://jvi.asm.org/cgi/pmidlookup?view=long&pmid=17344287.
51. ^ Stein DA, Huang CY, Silengo S, et al. (September 2008). "Treatment of AG129
mice with antisense morpholino oligomers increases survival time following
challenge with dengue 2 virus". The Journal of antimicrobial chemotherapy 62
(3): 555–65. doi:10.1093/jac/dkn221. PMID 18567576.
http://jac.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=18567576.
 52. ^ a b Fua, Guoliang; Leesa, Rosemary S.; Nimmoa, Derric; Awc, Diane; Jina, Li;
Graya, Pam; Berendonkb, Thomas U.; White-Cooperb, Helen et al. (2010).
"Female-specific flightless phenotype for mosquito control". Proc. Natl. Acad.
Sci. 107 (10): 4550. doi:10.1073/pnas.1000251107. PMID 20176967.
PMC 2826341.
http://www.pnas.org/content/early/2010/02/16/1000251107.full.pdf..
53. ^ 'Lame' mosquitoes to stop dengue. BBC News. 23 February 2010.
http://news.bbc.co.uk/2/hi/health/8528417.stm..
54. ^ "Discovering Dengue Drugs – Together". University of Texas Medical Branch.
2009-01-04. http://www.utmb.edu/discoveringdenguedrugs-together/. Retrieved
2009-01-04.

[edit] External links

• Dengue: CDC home page The Centers for Disease Control and Prevention (CDC)
• Dengue: Clinical and Public Health Aspects, The Centers for Disease Control and
Prevention (CDC)
• Dengue haemorrhagic fever: diagnosis, treatment, prevention and control 2nd
edition. Geneva : World Health Organization.
• The NCBI Virus Variation Resources The Virus Variation Resources at The
National Center for Biotechnology Information (NCBI).
• Dengue Virus Net Information site for dengue symptoms, prevention, treatment,
vaccine research and outbreak news.

[hide]
v•d•e